

STroke inpatient secOndary Prevention: current status and continuous care improvement

Submission date 30/03/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 26/04/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 22/09/2021	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Wang Yongjun

Contact details
Beijing Tiantan Hospital
Tiantan Xili 6
Chongwen District
Beijing
China
100050
-
yongjunw@hotmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

STroke inpatient secOndary Prevention: current status and continuous care improvement

Acronym

STOP

Study objectives

The secondary prevention collaborative system is hospitalised; for doctors, it can increase the coincidence with the therapeutic regime and for patients, it can improve the compliance to the risk factor controls.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval gained from the Beijing Tiantan Hospital Capital Medical University Ethics Board on the January 19, 2007.

Study design

The trial is a prospective cohort study. Because the staff take turns to care for the patients in different wards, it is impossible to randomise grouping.

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Ischaemic stroke and Transient Ischaemic Attack (TIA)

Interventions

The conception of this project is to organise the effective stroke secondary prevention program, which is initiated at hospitalisation, into the whole course of stroke care, thus improving the prophylaxis of inpatients with ischaemic stroke or TIA, on medical compliance, confidence, preventive efficacy.

There are three treatments:

1. The medical treatment includes drug treatments of hypertension, dyslipoidemia, carotid stenosis, and anti-platelet agents

2. The surgical treatment includes carotid endarterectomy, carotid angioplasty and stent
3. Lifestyle modifications comprise of stopping smoking, weight control and public education

The program is practiced on all patients who have a probability of scleratheromic stroke.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. The coincidence with the therapeutic regimen
2. The compliance to the risk factor controls

Secondary outcome measures

The reoccurrence rate of vascular issues.

Overall study start date

01/10/2006

Completion date

01/06/2008

Eligibility

Key inclusion criteria

1. Age equal to or older than 18 years
2. Ischaemic event (infarction/Transient Ischaemic Attack [TIA]) within two weeks
3. Diagnosis of infarction or TIA
Infarction:
 - a. sudden or rapid onset of focal ischaemic neurological impairments by all kinds of reasons
 - b. the impairments last more than 24 hoursTIA:
 - a. sudden or rapid onset of focal ischaemic neurological impairments by all kinds of reasons
 - b. the impairments are within 24 hours (the diagnosis could be made if the patient have one of the symptoms: amaurosis fugax, dysphasia, movement disorder such as weakness or clumsiness; but such symptoms as diplopia, scintillation, scotosis, vertigo, memory disorder and ataxia cannot support the diagnoses; the symptoms that may be caused by migraine are ruled out)
4. No matter which one it is, all have either a Computed Tomography (CT) or a Magnetic Resonance Imaging (MRI) scan, to preclude haemorrhage or other non-ischaemic nerve system diseases
5. All the diagnoses have been confirmed and registered by the research centre neurologist
6. Patient resident in Beijing for at least one year
7. Patient consents to follow up for at least one year
8. Mechanism of the event is probably infarction/TIA due to artery scleratheroma
9. More than one modifiable risk factors of Cardiovascular Disease (CVD)
10. The case collected in each research centre should be consecutive. Even the patients who qualified but reject to join in, should also be added in the sum and registered with the basic items such as name, sex, age

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

1600

Key exclusion criteria

1. Pregnancy
2. Silent infarction without symptoms or focal signs
3. Venous infarction
4. Other causes of ischaemic stroke but not scleratheromic. For example, cardiac resource, hyper-coagulation, dissection, vasculitis, medical resource such as the complications of carotid endarterectomy or angiography, traumatic resource, aura migraine, epilepsy, other non-ischaemic stroke
5. Reject to join in the study
6. Event episode concomitant with cardiac disease, cardiac insufficiency, hepatosis, renal inadequacy, respiratory failure, malignant tumour etc., and anticipate not to accomplish the one year-follow up
7. Glasgow Coma Score (GCS) less than four

Date of first enrolment

01/10/2006

Date of final enrolment

01/06/2008

Locations**Countries of recruitment**

China

Study participating centre

Beijing Tiantan Hospital

Beijing

China

100050

Sponsor information

Organisation

Beijing Tiantan Hospital (China)

Sponsor details

c/o Professor Wang Yongjun

Tiantan Xili 6

Chongwen District

Beijing

China

100050

-

yongjunw@hotmail.com

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/003regz62>

Funder(s)**Funder type**

Government

Funder Name

Beijing Municipal Science & Technology Commission (China)

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration